BSE: ZYDUSLIFE - Zydus Lifesciences Limited

Rentabilität für sechs Monate: -14.26%
Dividendenrendite: +0.72%
Sektor: Healthcare

Aktionsplan Zydus Lifesciences Limited


Über das Unternehmen Zydus Lifesciences Limited

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments.

weitere details
It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

ISIN INE010B01027
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.7249
Дивиденд ао 3
Сайт https://zyduslife.com
Цена ао 907
Preisänderung pro Tag: +0.691% (868.25)
Preisänderung pro Woche: +1.71% (859.55)
Preisänderung pro Monat: -0.9405% (882.55)
Preisänderung über 3 Monate: -12.64% (1000.8)
Preisänderung über sechs Monate: -14.26% (1019.65)
Preisänderung pro Jahr: -6.54% (935.45)
Preisänderung über 3 Jahre: +135.11% (371.85)
Preisänderung über 5 Jahre: +235.99% (260.2)
Preisänderung seit Jahresbeginn: -9.82% (969.5)

Unterschätzung

Name Bedeutung Grad
P/S 5.29 2
P/BV 4.55 3
P/E 26.06 6
EV/EBITDA 14.65 7
Gesamt: 5

Effizienz

Name Bedeutung Grad
ROA, % 14.03 4
ROE, % 20.67 7
Gesamt: 4

Dividenden

Name Bedeutung Grad
Div yield, % 0.7249 1.8
DSI 0.8571 8.57
Gesamt: 2.38

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 37.72 5
Rentabilität Ebitda, % 36.84 5
Rentabilität EPS, % 233.73 10
Gesamt: 7.2



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Sharvil Pankajbhai Patel MD & Executive Director 262.5M 1979 (46 Jahre)
Dr. Ganesh Narayan Nayak COO & Executive Director 120M 1955 (70 Jahre)
Mr. Punit Patel President & CEO of America N/A
Mr. Nitinkumar Dalsukhray Parekh Chief Financial Officer 54.31M
Mr. Arvind Bothra Head of Investor Relations N/A
Mr. Dhaval Narendra Soni Company Secretary & Compliance Officer 2.09M

Adresse: India, Ahmedabad, Zydus Corporate Park - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://zyduslife.com